Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 25;22(3):1166.
doi: 10.3390/ijms22031166.

Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma

Vincenzo De Falco  1 , Stefania Napolitano  1 , Daniela Esposito  2 , Luigi Pio Guerrera  1 , Davide Ciardiello  1 , Luigi Formisano  2 , Teresa Troiani  1
Affiliations
Review

Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma

Vincenzo De Falco et al. Int J Mol Sci. .

Abstract

Cutaneous melanoma is considered a rare tumor, although it is one of the most common cancers in young adults and its incidence has risen in the last decades. Targeted therapy, with BRAF and MEK inhibitors, and immunotherapy revolutionized the treatment of metastatic melanoma but there is still a considerable percentage of patients with primary or acquired resistance to these therapies. Recently, oncology researchers directed their attention at the role of long non-coding RNAs (lncRNAs) in different types of cancers, including melanoma. lncRNAs are RNA transcripts, initially considered "junk sequences", that have been proven to have a crucial role in the fine regulation of physiological and pathological processes of different tissues. Furthermore, they are more expressed in tumors than protein-coding genes, constituting perfect candidates either as biomarkers (diagnostic, prognostic, predictive) or as therapeutic targets. In this work, we reviewed all the literature available for lncRNA in melanoma, elucidating all the potential roles in this tumor.

Keywords: biomarkers; cancer therapy; lncRNA; melanoma; skin cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest for this research.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cancer Stat Facts: Melanoma of the Skin, NCI SEER. [(accessed on 6 November 2020)]; Available online: https://seer.cancer.gov/statfacts/html/melan.html.
    1. Potrony M., Badenas C., Aguilera P., Puig-Butille J.A., Carrera C., Malvehy J., Puig S. Update in genetic susceptibility in melanoma. Ann. Transl. Med. 2015;3 doi: 10.3978/j.issn.2305-5839.2015.08.11. - DOI - PMC - PubMed
    1. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A.J.R., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Børresen-Dale A.-L., et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. doi: 10.1038/nature12477. - DOI - PMC - PubMed
    1. Tsao H., Chin L., Garraway L.A., Fisher D.E. Melanoma: From mutations to medicine. Genes Dev. 2012;26:1131–1155. doi: 10.1101/gad.191999.112. - DOI - PMC - PubMed
    1. Giunta E.F., De Falco V., Napolitano S., Argenziano G., Brancaccio G., Moscarella E., Ciardiello D., Ciardiello F., Troiani T. Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. Ther. Adv. Med. Oncol. 2020;12 doi: 10.1177/1758835920925219. - DOI - PMC - PubMed